Hydrochlorothiazide crystal and candesartan cilexetil hydrochlorothiazide medicinal combination thereof

Abstract

The invention discloses a hydrochlorothiazide crystal and a candesartan cilexetil hydrochlorothiazide medicinal combination thereof. The characteristic peaks of the hydrochlorothiazide crystal in an X-ray powder diffraction pattern, which are measured and obtained by using a Cu-K[alpha] ray, are displayed when 2[theta] is 4.1 degrees, 8.2 degrees, 9.8 degrees, 12.1 degrees, 15.1 degrees, 16.7 degrees, 19.3 degrees, 20.0 degrees, 22.1 degrees, 23.3 degrees and 26.8 degrees. The combination comprises 4-20 parts of candesartan cilexetil, 10-15 parts of the hydrochlorothiazide crystal, 10-50 parts of pregelatinized starch, 15-35 parts of microcrystalline cellulose PH102, 10-45 parts of crosslinked polyvinylpyrrolidone and 0.5-1 part of magnesium stearate. The medicinal combination has a reasonable prescription, stable and reliable quality, and better disintegration time limit and dissolution rate; a direct powder tabletting process is adopted; the process is simple; the production period is short; the production cost is low; and the industrialized production is facilitated.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a hydrochlorothiazide crystal and a candesartan cilexetil hydrochlorothiazide pharmaceutical composition. Background technique [0002] Hypertension is the most common cardiovascular disease and a major public health problem worldwide. In 1991, my country conducted a sample survey of 940,000 people over the age of 15. Statistics show that the prevalence of hypertension in my country has reached 11.26%, which is 25% higher than that in the 10 years from 1979 to 1990. There are more than 130 million hypertensive patients in my country. . Moreover, this upward momentum continues. Statistics also show that the treatment rate of hypertension is 17.4% in urban areas and 5.4% in rural areas; the control rate (systolic blood pressure<140mmHg and diastolic blood pressure<90mmHg after treatment) is only 2.9%. From the above statistics, it can be seen that the prevalenc...

AI Technical Summary

Problems solved by technology

[0014] Patent application CN101659643A discloses a crystal form of hydrochlorothiazide and its use. Aiming at the problems of slow dissolution and poor bioavailability of hydrochlorothiazide commonly found in the prior art, a new hydrochlorothiazide crystal form III (such as figure 2 shown), the results show that the dissolution rate of preparations made of hydrochlorothiazide crystal form III or the composition of hydrochlorothiazide III and other types of antihypertensive drugs can reach a level similar to that of similar foreign products, and solve the problem of hydrochlorothiazide dissolution to a certain extent. slow speed problem

However, the stability of the preparation has not been significantly improved, and the curative effect of the pharmaceutical preparation is not ideal. In view of this, the present invention is proposed

Images